Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Gemcitabine is the mainstay of palliative chemotherapy for patients with advanced pancreatic
cancer (APC). Recent randomized trials have shown increased clinical benefit with the
addition of oxaliplatin and prolonged median survival with the addition of capecitabine to
gemcitabine. Gemcitabine, capecitabine and oxaliplatin are 3 newer, well tolerated anticancer
drugs with mild and non-overlapping toxicity profiles. We therefore propose a dose-finding
and safety study of the triple combination gemcitabine, capecitabine and oxaliplatin in
patients with APC (Phase I part), followed by a phase II part to assess preliminary efficacy
of this triple combination.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborators:
Roche Pharma AG Sanofi Swiss Cancer League Swiss National Science Foundation